Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch, executives said on the company’s 2026 first-quarter earnings call.
Chief Executive Officer Scott Plesha said the quarter reflected “strong execution and progress” across several areas, led by increased prescriptions for ZELSUVMI, a topical nitric oxide-releasing treatment for molluscum contagiosum in patients one year of age and older. ZELSUVMI launched in July 2025 and is the first FDA-approved therapy for molluscum contagiosum that can be applied at home by parents, patients or caregivers, according to the company.
